epilepsy

Enveric Biosciences Inc (NASDAQ:ENVB), a biotechnology company focused on neuropsychiatric treatment development, has secured five new U.S. patents for its EVM301 portfolio. This latest additions bring Enveric's total to nine issued U.S. patents, enhancing the intellectual property surrounding its...

Truist Securities initiated coverage on Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH), citing it as a CNS-focused biotech with high-value epilepsy assets. The company plans to advance its lead drug bexicaserin (LP352), into the Phase 3 program later this year. The FDA has granted Breakthrough...

Unexpected falls, stiff muscles, dazed behavior, memory gaps, mumbling or no response, sudden bursts of anger and fear are all symptoms of epilepsy, which is one of the most common childhood brain disorders. Now imagine your own child having up to 300 seizures a day. That's the...

Receptor Life Sciences (RLS), a pharmaceutical company developing innovative therapies to address central nervous system disorders, recently announced it’s expanding the potential clinical utility of RLS103, a dry powder inhaled cannabidiol (CBD)​​​​​​ into epilepsy treatment. Dry...

Belgian-based UCB SA (OTC: UCBJF) has agreed to buy Zogenix Inc (NASDAQ: ZGNX), a U.S. maker of drugs to treat seizures and rare diseases, for $1.9 billion, expanding its portfolio to treat epilepsy. Investors will get $26 in cash for every Zogenix share, plus a potential...

Epileptic seizure frequency fell by an average of 86% among ten children treated with whole-plant medicinal cannabis, reveals a case series published in the open-access journal BMJ Paediatrics Open. None of the children had responded to other treatments, including the only cannabidiol (...

Taysha Gene Therapies Inc (NASDAQ: TSHA) announced a late-breaking abstract and poster presentation on preclinical data for TSHA-105 for SLC13A5-related epilepsy. Data were shared at the American Epilepsy Society Annual Meeting. In knockout mouse models of SLC13A5 deficiency,...

Stoke Therapeutics Inc (NASDAQ: STOK) announced highlights from five presentations related to the ongoing clinical development of STK-001 being made at the American Epilepsy Society 2021 Annual Meeting. STK-001 is under development to target the underlying cause of Dravet syndrome,...

Xenon Pharmaceuticals Inc (NASDAQ: XENE) announced additional positive data from new sub-analyses of Phase 2b X-TOLE trial of XEN1101 in adult patients with focal epilepsy. The Data will be presented at the Annual Meeting of the American Epilepsy Society. Additional primary and...

Xenon Pharmaceuticals Inc (NASDAQ: XENE) has reported topline results from the Phase 2b X-TOLE trial evaluating XEN1101 as an adjunctive treatment in adult patients with focal epilepsy. The trial met its primary efficacy endpoint with XEN1101, demonstrating a statistically...

The European Commission has granted Orphan Drug designation to Taysha Gene Therapies Inc's (NASDAQ: TSHA) TSHA-105, AAV9-based gene therapy for SLC13A5-related epilepsy. Related: Taysha Gene Secures $100M In Debt Financing For Support Pipeline Development SLC13A5...

Pfizer Inc (NYSE: PFE) and Flynn Pharma Ltd have been accused by the U.K.'s competition watchdog of illegally overcharging the National Health Service (NHS) for anti-epilepsy drugs. What Happened: The Competition and Markets Authority (CMA) said that the companies used...

Marinus Pharmaceuticals Inc (NASDAQ: MRNS) has submitted a marketing application to the FDA seeking approval for its lead product candidate, ganaxolone, to treat seizures associated with CDKL5 deficiency disorder (CDD). An application filing notification letter from the FDA is...

OPKO Health Inc (NASDAQ: OPK) has entered into an exclusive worldwide agreement with privately-held CAMP4 Therapeutics Corporation (CAMP4) to develop, manufacture, and commercialize therapeutics utilizing the AntagoNAT technology. AntagoNATs are oligonucleotide compounds...

Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) presents sleep data from an open-label Phase 2 trial evaluating Zygel for developmental & epileptic encephalopathies (DEE) and autism spectrum disorder (ASD). Results were presented at the Associated Professional Sleep Societies SLEEP...